Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Prostate Cancer

Accreditation types: 1.25 ABIM MOC, ABS MOC, CME

Expires: April 2027

To play this presentation please log in.

Don't have an account?

Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

Faculty

Andrew J Armstrong

Faculty

Andrew J Armstrong

MD, ScM

Duke University, Durham, North Carolina

Professor of Medicine, Surgery, Pharmacology and Cancer Biology, Director of Research, Duke Cancer Institute Center for Prostate and Urologic Cancers, Division of Medical Oncology, Departments of Medicine and Urology

Scott T Tagawa

Faculty

Scott T Tagawa

MD, MS

Weill Cornell Medicine, New York, New York

Professor of Medicine and Urology

Meyer Cancer Center, New York, New York

Leader, GU Disease Management Team

TARGET AUDIENCE
This program is intended for medical and radiation oncologists, urologists and other healthcare providers involved in the treatment of prostate cancer.

LEARNING OBJECTIVES

  • Infer how various clinical and biological factors affect the risk of prostate cancer recurrence after local therapy, and design appropriate treatment plans for individual patients with consideration of the potential benefits and risks of new and established forms of hormonal therapy.
  • Evaluate the published research database supporting the FDA approvals of secondary hormonal agents for the management of nonmetastatic prostate cancer, and apply this information in the discussion of nonresearch treatment options.
  • Explore available data with the use of treatment intensification with cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer (mHSPC), and effectively integrate these strategies into current clinical management algorithms.
  • Appreciate the biological rationale for targeting the PI3K/AKT/mTOR pathway in prostate cancer, and evaluate available data with novel AKT inhibitors in combination with hormonal therapy for patients with mHSPC and PTEN deficiency.
  • Assess the available research database supporting the use of PARP inhibitors in combination with androgen receptor pathway inhibitors for patients with metastatic prostate cancer harboring a homologous recombination repair gene alteration, and discern how to optimally incorporate these agents into current clinical management algorithms.
  • Review available Phase III data documenting the efficacy of various forms of radioligand therapy for patients with metastatic prostate cancer, and consider the current and future clinical role of these strategies.
  • Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Video Proceedings: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/YIR2025/Prostate/Video/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Andrew J Armstrong, MD, ScM
Professor of Medicine, Surgery, Pharmacology and Cancer Biology
Director of Research
Duke Cancer Institute Center for Prostate and Urologic Cancers
Division of Medical Oncology
Departments of Medicine and Urology
Duke University
Durham, North Carolina

Advisory Committees: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Merck, Pfizer Inc, Precede Biosciences, Sumitomo Pharma America, Telix Pharmaceuticals Limited; Consulting Agreements: Amgen Inc, Astellas, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Novartis, Pfizer Inc; Contracted Research: Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, FibroGen Inc, Janssen Biotech Inc, Merck, Novartis, Pathos, Pfizer Inc.

Scott T Tagawa, MD, MS
Professor of Medicine and Urology
Weill Cornell Medicine
Leader, GU Disease Management Team
Meyer Cancer Center
New York, New York

Consulting Agreements: AbbVie Inc, Abdera Therapeutics, Bayer HealthCare Pharmaceuticals, Biohaven, Blue Earth Diagnostics, Boston Scientific Corporation, Clarity Pharmaceuticals, Convergent Therapeutics Inc, Daiichi Sankyo Inc, EMD Serono Inc, GE Healthcare, Gilead Sciences Inc, Johnson & Johnson, Lantheus, Lilly, Merck, Myovant Sciences, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Telix Pharmaceuticals Limited; Contracted Research: AIQ Solutions, Bayer HealthCare Pharmaceuticals, Clarity Pharmaceuticals, Gilead Sciences Inc, Janux Therapeutics, Johnson & Johnson, Lilly, Merck, Novartis, Pfizer Inc, Telix Pharmaceuticals Limited; Data and Safety Monitoring Boards/Committees: Boston Scientific Corporation; Stock OPTIONS — Private Companies: Convergent Therapeutics.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Merck, Novartis, and Sumitomo Pharma America and Pfizer Inc.

Release date: April 2026
Expiration date: April 2027

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Aggarwal R et al. Final results from PRESTO: A phase III open-label study of combined androgen blockade in patients (pts) with high-risk biochemically relapsed prostate cancer (BRPC) (AFT-19). ESMO 2025;Abstract LBA88.

Armstrong AJ et al. Trial design and objectives for patients with prostate cancer: Recommendations from the prostate cancer working group 4. J Clin Oncol 2026;[Online ahead of print]. Abstract

De Bono JS et al. IDeate-Prostate02: A phase 1/2, open-label umbrella substudy of ifinatamab deruxtecan-based treatment combinations or as monotherapy in participants with previously treated metastatic castration-resistant prostate cancer. Genitourinary Cancers Symposium 2026;Abstract TPS297.

De La Cerda J et al. Safety and tolerability of relugolix in combination with abiraterone or apalutamide for treatment of patients with advanced prostate cancer: Data from a 52-week clinical trial. Target Oncol 2025;20(3):503-17. Abstract

Emmett L et al. PSMAcTION trial-in-progress: A phase II/III randomized trial of [225Ac]Ac-PSMA-617 (225Ac-PSMA-617) versus standard of care in patients with PSMA-positive metastatic castration-resistant prostate cancer who progressed on or after [177Lu]Lu-PSMA therapy. ESMO 2025;Abstract 2516TiP.

Fizazi K et al. Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. Ann Oncol 2026;37(1):53-68. Abstract

Fizazi K et al. OMAHA-004: Phase 3 trial of CYP11A1 inhibitor opevesostat versus androgen receptor pathway inhibitor (ARPI) switch in participants with metastatic castration-resistant prostate cancer (mCRPC) after a prior ARPI. Genitourinary Cancers Symposium 2026;Abstract TPS299.

Fizazi K et al. Final overall survival and safety analyses of the phase III PSMAfore trial of [(177)Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer. Ann Oncol 2025;36(11):1319-30. Abstract

Francolini G et al. Ultra-hypofractionated radiotherapy and concomitant oral relugolix for treatment of intermediate risk prostate cancer (ULTRA-HERO). Genitourinary Cancers Symposium 2026;Abstract TPS411.

Freedland SJ et al. Effects of enzalutamide on the sexual activity of patients with biochemically recurrent prostate cancer: A post hoc analysis of patient-reported outcomes in the EMBARK study. Eur Urol 2025;87(5):507-11. Abstract

Gallardo E et al. Final overall survival results from the EORTC 1333/PEACE-3 trial: Enzalutamide with or without radium-223 in metastatic castration-resistant prostate cancer. Genitourinary Cancers Symposium 2026;Abstract 15.

George DJ et al. Patient reported outcomes (PRO) and tolerability of capivasertib (capi) plus abiraterone (abi) versus placebo (pbo) plus abi in patients (pts) with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281. Genitourinary Cancers Symposium 2026;Abstract 14.

Grimm M-O et al. 3-weekly docetaxel 75 mg/m2 vs 2-weekly docetaxel 50 mg/m2 in combination with darolutamide + ADT in patients with mHSPC: Results from the randomised phase III ARASAFE trial. ESMO 2025;Abstract LBA92.

McKay RR et al. IDeate-Prostate01: A phase 3, randomized, open-label study of ifinatamab deruxtecan versus docetaxel in participants with previously treated metastatic castration-resistant prostate cancer. Genitourinary Cancers Symposium 2026;Abstract TPS294.

McKay RR et al. Phase III, randomized, double-blind, placebo-controlled study of adjuvant saruparib (AZD5305) in patients with BRCAm localized high-risk prostate cancer who are receiving radiotherapy and androgen deprivation therapy (EvoPAR-Prostate02). Genitourinary Cancers Symposium 2026;Abstract TPS412.

McKay RR et al. Quality of life, adherence, and adverse events among patients with advanced prostate cancer treated with relugolix: 6-month results of the OPTYX multicenter registry. Genitourinary Cancers Symposium 2026;Abstract 122.

Morgans AK et al. Health-related quality of life (HRQoL) outcomes with darolutamide in the phase 3 ARANOTE trial. ASCO 2025;Abstract 5004.

Sathekge MM et al. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): A multicentre, retrospective study. Lancet Oncol 2024;25(2):175-83. Abstract

Shore ND et al. Improved survival with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med 2026;394(6):563-75. Abstract

Stein MN et al. Pasritamig, a first-in-class, bispecific T-cell engager targeting human kallikrein 2, in metastatic castration-resistant prostate cancer: A phase I study. J Clin Oncol 2025;43(22):2515-26. Abstract

Tagawa ST et al. Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition). ESMO 2025;Abstract LBA6.

Yu EY et al. OMAHA-003: Phase 3 trial of CYP11A1 inhibitor opevesostat versus androgen receptor pathway inhibitor (ARPI) switch in participants (pts) with metastatic castration-resistant prostate cancer (mCRPC) after ARPI and taxane-based chemotherapy. Genitourinary Cancers Symposium 2026;Abstract TPS298.

Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Prostate Cancer

Accreditation types: 1 ABIM MOC, ABS MOC, CME

Expires: April 2027

To play this presentation please log in.

Don't have an account?

Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

Faculty

Andrew J Armstrong

Faculty

Andrew J Armstrong

MD, ScM

Duke University, Durham, North Carolina

Professor of Medicine, Surgery, Pharmacology and Cancer Biology, Director of Research, Duke Cancer Institute Center for Prostate and Urologic Cancers, Division of Medical Oncology, Departments of Medicine and Urology

Scott T Tagawa

Faculty

Scott T Tagawa

MD, MS

Weill Cornell Medicine, New York, New York

Professor of Medicine and Urology

Meyer Cancer Center, New York, New York

Leader, GU Disease Management Team

TARGET AUDIENCE
This program is intended for medical and radiation oncologists, urologists and other healthcare providers involved in the treatment of prostate cancer.

LEARNING OBJECTIVES

  • Infer how various clinical and biological factors affect the risk of prostate cancer recurrence after local therapy, and design appropriate treatment plans for individual patients with consideration of the potential benefits and risks of new and established forms of hormonal therapy.
  • Appraise published research findings on optimal management approaches for patients with biochemical recurrence after local treatment for prostate cancer, and counsel appropriate individuals regarding the potential benefits of FDA-approved systemic treatment options.
  • Evaluate the published research database supporting the FDA approvals of secondary hormonal agents for the management of nonmetastatic prostate cancer, and apply this information in the discussion of nonresearch treatment options.
  • Explore available data with the use of treatment intensification with cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer (mHSPC), and effectively integrate these strategies into current clinical management algorithms.
  • Establish an evidence-based approach to the selection and sequencing of available therapeutic options for patients with metastatic castration-resistant prostate cancer, considering age, comorbidities, prior therapeutic exposure and other relevant clinical and biological factors.
  • Assess the available research database supporting the use of PARP inhibitors in combination with androgen receptor pathway inhibitors for patients with metastatic prostate cancer harboring a homologous recombination repair gene alteration, and discern how to optimally incorporate these agents into current clinical management algorithms.
  • Appreciate the biological rationale for targeting the PI3K/AKT/mTOR pathway for prostate cancer, and evaluate available and emerging data with novel AKT inhibitors in combination with hormonal therapy for patients with mHSPC and PTEN deficiency.
  • Review available and emerging Phase III data documenting the efficacy of various forms of radioligand therapy for patients with metastatic prostate cancer, and consider the current and potential future clinical role of these strategies.
  • Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
Successful completion of these CME activities, which includes participation in the evaluation component and a post-test, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/YIR2025/Prostate/Presentations/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Andrew J Armstrong, MD, ScM
Professor of Medicine, Surgery, Pharmacology and Cancer Biology
Director of Research
Duke Cancer Institute Center for Prostate and Urologic Cancers
Division of Medical Oncology
Departments of Medicine and Urology
Duke University
Durham, North Carolina

Advisory Committees: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Merck, Pfizer Inc, Precede Biosciences, Sumitomo Pharma America, Telix Pharmaceuticals Limited; Consulting Agreements: Amgen Inc, Astellas, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Novartis, Pfizer Inc; Contracted Research: Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, FibroGen Inc, Janssen Biotech Inc, Merck, Novartis, Pathos, Pfizer Inc.

Scott T Tagawa, MD, MS
Professor of Medicine and Urology
Weill Cornell Medicine
Leader, GU Disease Management Team
Meyer Cancer Center
New York, New York

Consulting Agreements: AbbVie Inc, Abdera Therapeutics, Bayer HealthCare Pharmaceuticals, Biohaven, Blue Earth Diagnostics, Boston Scientific Corporation, Clarity Pharmaceuticals, Convergent Therapeutics Inc, Daiichi Sankyo Inc, EMD Serono Inc, GE Healthcare, Gilead Sciences Inc, Johnson & Johnson, Lantheus, Lilly, Merck, Myovant Sciences, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Telix Pharmaceuticals Limited; Contracted Research: AIQ Solutions, Bayer HealthCare Pharmaceuticals, Clarity Pharmaceuticals, Gilead Sciences Inc, Janux Therapeutics, Johnson & Johnson, Lilly, Merck, Novartis, Pfizer Inc, Telix Pharmaceuticals Limited; Data and Safety Monitoring Boards/Committees: Boston Scientific Corporation; Stock OPTIONS — Private Companies: Convergent Therapeutics.

MODERATOR —Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Merck, Novartis, and Sumitomo Pharma America and Pfizer Inc.

Release date: April 2026
Expiration date: April 2027

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Aggarwal R et al. Final results from PRESTO: A phase III open-label study of combined androgen blockade in patients (pts) with high-risk biochemically relapsed prostate cancer (BRPC) (AFT-19). ESMO 2025;Abstract LBA88.

Armstrong AJ et al. Trial design and objectives for patients with prostate cancer: Recommendations from the prostate cancer working group 4. J Clin Oncol 2026;[Online ahead of print]. Abstract

De Bono JS et al. IDeate-Prostate02: A phase 1/2, open-label umbrella substudy of ifinatamab deruxtecan-based treatment combinations or as monotherapy in participants with previously treated metastatic castration-resistant prostate cancer. Genitourinary Cancers Symposium 2026;Abstract TPS297.

De La Cerda J et al. Safety and tolerability of relugolix in combination with abiraterone or apalutamide for treatment of patients with advanced prostate cancer: Data from a 52-week clinical trial. Target Oncol 2025;20(3):503-17. Abstract

Emmett L et al. PSMAcTION trial-in-progress: A phase II/III randomized trial of [225Ac]Ac-PSMA-617 (225Ac-PSMA-617) versus standard of care in patients with PSMA-positive metastatic castration-resistant prostate cancer who progressed on or after [177Lu]Lu-PSMA therapy. ESMO 2025;Abstract 2516TiP.

Fizazi K et al. Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. Ann Oncol 2026;37(1):53-68. Abstract

Fizazi K et al. OMAHA-004: Phase 3 trial of CYP11A1 inhibitor opevesostat versus androgen receptor pathway inhibitor (ARPI) switch in participants with metastatic castration-resistant prostate cancer (mCRPC) after a prior ARPI. Genitourinary Cancers Symposium 2026;Abstract TPS299.

Fizazi K et al. Final overall survival and safety analyses of the phase III PSMAfore trial of [(177)Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer. Ann Oncol 2025;36(11):1319-30. Abstract

Francolini G et al. Ultra-hypofractionated radiotherapy and concomitant oral relugolix for treatment of intermediate risk prostate cancer (ULTRA-HERO). Genitourinary Cancers Symposium 2026;Abstract TPS411.

Freedland SJ et al. Effects of enzalutamide on the sexual activity of patients with biochemically recurrent prostate cancer: A post hoc analysis of patient-reported outcomes in the EMBARK study. Eur Urol 2025;87(5):507-11. Abstract

Gallardo E et al. Final overall survival results from the EORTC 1333/PEACE-3 trial: Enzalutamide with or without radium-223 in metastatic castration-resistant prostate cancer. Genitourinary Cancers Symposium 2026;Abstract 15.

George DJ et al. Patient reported outcomes (PRO) and tolerability of capivasertib (capi) plus abiraterone (abi) versus placebo (pbo) plus abi in patients (pts) with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281. Genitourinary Cancers Symposium 2026;Abstract 14.

Grimm M-O et al. 3-weekly docetaxel 75 mg/m2 vs 2-weekly docetaxel 50 mg/m2 in combination with darolutamide + ADT in patients with mHSPC: Results from the randomised phase III ARASAFE trial. ESMO 2025;Abstract LBA92.

McKay RR et al. IDeate-Prostate01: A phase 3, randomized, open-label study of ifinatamab deruxtecan versus docetaxel in participants with previously treated metastatic castration-resistant prostate cancer. Genitourinary Cancers Symposium 2026;Abstract TPS294.

McKay RR et al. Phase III, randomized, double-blind, placebo-controlled study of adjuvant saruparib (AZD5305) in patients with BRCAm localized high-risk prostate cancer who are receiving radiotherapy and androgen deprivation therapy (EvoPAR-Prostate02). Genitourinary Cancers Symposium 2026;Abstract TPS412.

McKay RR et al. Quality of life, adherence, and adverse events among patients with advanced prostate cancer treated with relugolix: 6-month results of the OPTYX multicenter registry. Genitourinary Cancers Symposium 2026;Abstract 122.

Morgans AK et al. Health-related quality of life (HRQoL) outcomes with darolutamide in the phase 3 ARANOTE trial. ASCO 2025;Abstract 5004.

Sathekge MM et al. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): A multicentre, retrospective study. Lancet Oncol 2024;25(2):175-83. Abstract

Shore ND et al. Improved survival with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med 2026;394(6):563-75. Abstract

Stein MN et al. Pasritamig, a first-in-class, bispecific T-cell engager targeting human kallikrein 2, in metastatic castration-resistant prostate cancer: A phase I study. J Clin Oncol 2025;43(22):2515-26. Abstract

Tagawa ST et al. Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition). ESMO 2025;Abstract LBA6.

Yu EY et al. OMAHA-003: Phase 3 trial of CYP11A1 inhibitor opevesostat versus androgen receptor pathway inhibitor (ARPI) switch in participants (pts) with metastatic castration-resistant prostate cancer (mCRPC) after ARPI and taxane-based chemotherapy. Genitourinary Cancers Symposium 2026;Abstract TPS298.

Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Prostate Cancer

Accreditation types: 1 ABIM MOC, ABS MOC, CME

Expires: April 2027

To play this presentation please log in.

Don't have an account?

Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

Faculty

Andrew J Armstrong

Faculty

Andrew J Armstrong

MD, ScM

Duke University, Durham, North Carolina

Professor of Medicine, Surgery, Pharmacology and Cancer Biology, Director of Research, Duke Cancer Institute Center for Prostate and Urologic Cancers, Division of Medical Oncology, Departments of Medicine and Urology

Scott T Tagawa

Faculty

Scott T Tagawa

MD, MS

Weill Cornell Medicine, New York, New York

Professor of Medicine and Urology

Meyer Cancer Center, New York, New York

Leader, GU Disease Management Team

TARGET AUDIENCE
This program is intended for medical and radiation oncologists, urologists and other healthcare providers involved in the treatment of prostate cancer.

LEARNING OBJECTIVES

  • Infer how various clinical and biological factors affect the risk of prostate cancer recurrence after local therapy, and design appropriate treatment plans for individual patients with consideration of the potential benefits and risks of new and established forms of hormonal therapy.
  • Appraise published research findings on optimal management approaches for patients with biochemical recurrence after local treatment for prostate cancer, and counsel appropriate individuals regarding the potential benefits of FDA-approved systemic treatment options.
  • Evaluate the published research database supporting the FDA approvals of secondary hormonal agents for the management of nonmetastatic prostate cancer, and apply this information in the discussion of nonresearch treatment options.
  • Explore available data with the use of treatment intensification with cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer (mHSPC), and effectively integrate these strategies into current clinical management algorithms.
  • Establish an evidence-based approach to the selection and sequencing of available therapeutic options for patients with metastatic castration-resistant prostate cancer, considering age, comorbidities, prior therapeutic exposure and other relevant clinical and biological factors.
  • Assess the available research database supporting the use of PARP inhibitors in combination with androgen receptor pathway inhibitors for patients with metastatic prostate cancer harboring a homologous recombination repair gene alteration, and discern how to optimally incorporate these agents into current clinical management algorithms.
  • Appreciate the biological rationale for targeting the PI3K/AKT/mTOR pathway for prostate cancer, and evaluate available and emerging data with novel AKT inhibitors in combination with hormonal therapy for patients with mHSPC and PTEN deficiency.
  • Review available and emerging Phase III data documenting the efficacy of various forms of radioligand therapy for patients with metastatic prostate cancer, and consider the current and potential future clinical role of these strategies.
  • Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program hasbeen specifically designed for the following ABIM specialty: medical oncology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/YIR2025/Prostate/Presentations/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Andrew J Armstrong, MD, ScM
Professor of Medicine, Surgery, Pharmacology and Cancer Biology
Director of Research
Duke Cancer Institute Center for Prostate and Urologic Cancers
Division of Medical Oncology
Departments of Medicine and Urology
Duke University
Durham, North Carolina

Advisory Committees: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Merck, Pfizer Inc, Precede Biosciences, Sumitomo Pharma America, Telix Pharmaceuticals Limited; Consulting Agreements: Amgen Inc, Astellas, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Novartis, Pfizer Inc; Contracted Research: Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, FibroGen Inc, Janssen Biotech Inc, Merck, Novartis, Pathos, Pfizer Inc.

Scott T Tagawa, MD, MS
Professor of Medicine and Urology
Weill Cornell Medicine
Leader, GU Disease Management Team
Meyer Cancer Center
New York, New York

Consulting Agreements: AbbVie Inc, Abdera Therapeutics, Bayer HealthCare Pharmaceuticals, Biohaven, Blue Earth Diagnostics, Boston Scientific Corporation, Clarity Pharmaceuticals, Convergent Therapeutics Inc, Daiichi Sankyo Inc, EMD Serono Inc, GE Healthcare, Gilead Sciences Inc, Johnson & Johnson, Lantheus, Lilly, Merck, Myovant Sciences, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Telix Pharmaceuticals Limited; Contracted Research: AIQ Solutions, Bayer HealthCare Pharmaceuticals, Clarity Pharmaceuticals, Gilead Sciences Inc, Janux Therapeutics, Johnson & Johnson, Lilly, Merck, Novartis, Pfizer Inc, Telix Pharmaceuticals Limited; Data and Safety Monitoring Boards/Committees: Boston Scientific Corporation; Stock OPTIONS — Private Companies: Convergent Therapeutics.

MODERATOR —Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Merck, Novartis, and Sumitomo Pharma America and Pfizer Inc.

Release date: April 2026
Expiration date: April 2027

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Aggarwal R et al. Final results from PRESTO: A phase III open-label study of combined androgen blockade in patients (pts) with high-risk biochemically relapsed prostate cancer (BRPC) (AFT-19). ESMO 2025;Abstract LBA88.

Armstrong AJ et al. Trial design and objectives for patients with prostate cancer: Recommendations from the prostate cancer working group 4. J Clin Oncol 2026;[Online ahead of print]. Abstract

De Bono JS et al. IDeate-Prostate02: A phase 1/2, open-label umbrella substudy of ifinatamab deruxtecan-based treatment combinations or as monotherapy in participants with previously treated metastatic castration-resistant prostate cancer. Genitourinary Cancers Symposium 2026;Abstract TPS297.

De La Cerda J et al. Safety and tolerability of relugolix in combination with abiraterone or apalutamide for treatment of patients with advanced prostate cancer: Data from a 52-week clinical trial. Target Oncol 2025;20(3):503-17. Abstract

Emmett L et al. PSMAcTION trial-in-progress: A phase II/III randomized trial of [225Ac]Ac-PSMA-617 (225Ac-PSMA-617) versus standard of care in patients with PSMA-positive metastatic castration-resistant prostate cancer who progressed on or after [177Lu]Lu-PSMA therapy. ESMO 2025;Abstract 2516TiP.

Fizazi K et al. Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. Ann Oncol 2026;37(1):53-68. Abstract

Fizazi K et al. OMAHA-004: Phase 3 trial of CYP11A1 inhibitor opevesostat versus androgen receptor pathway inhibitor (ARPI) switch in participants with metastatic castration-resistant prostate cancer (mCRPC) after a prior ARPI. Genitourinary Cancers Symposium 2026;Abstract TPS299.

Fizazi K et al. Final overall survival and safety analyses of the phase III PSMAfore trial of [(177)Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer. Ann Oncol 2025;36(11):1319-30. Abstract

Francolini G et al. Ultra-hypofractionated radiotherapy and concomitant oral relugolix for treatment of intermediate risk prostate cancer (ULTRA-HERO). Genitourinary Cancers Symposium 2026;Abstract TPS411.

Freedland SJ et al. Effects of enzalutamide on the sexual activity of patients with biochemically recurrent prostate cancer: A post hoc analysis of patient-reported outcomes in the EMBARK study. Eur Urol 2025;87(5):507-11. Abstract

Gallardo E et al. Final overall survival results from the EORTC 1333/PEACE-3 trial: Enzalutamide with or without radium-223 in metastatic castration-resistant prostate cancer. Genitourinary Cancers Symposium 2026;Abstract 15.

George DJ et al. Patient reported outcomes (PRO) and tolerability of capivasertib (capi) plus abiraterone (abi) versus placebo (pbo) plus abi in patients (pts) with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281. Genitourinary Cancers Symposium 2026;Abstract 14.

Grimm M-O et al. 3-weekly docetaxel 75 mg/m2 vs 2-weekly docetaxel 50 mg/m2 in combination with darolutamide + ADT in patients with mHSPC: Results from the randomised phase III ARASAFE trial. ESMO 2025;Abstract LBA92.

McKay RR et al. IDeate-Prostate01: A phase 3, randomized, open-label study of ifinatamab deruxtecan versus docetaxel in participants with previously treated metastatic castration-resistant prostate cancer. Genitourinary Cancers Symposium 2026;Abstract TPS294.

McKay RR et al. Phase III, randomized, double-blind, placebo-controlled study of adjuvant saruparib (AZD5305) in patients with BRCAm localized high-risk prostate cancer who are receiving radiotherapy and androgen deprivation therapy (EvoPAR-Prostate02). Genitourinary Cancers Symposium 2026;Abstract TPS412.

McKay RR et al. Quality of life, adherence, and adverse events among patients with advanced prostate cancer treated with relugolix: 6-month results of the OPTYX multicenter registry. Genitourinary Cancers Symposium 2026;Abstract 122.

Morgans AK et al. Health-related quality of life (HRQoL) outcomes with darolutamide in the phase 3 ARANOTE trial. ASCO 2025;Abstract 5004.

Sathekge MM et al. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): A multicentre, retrospective study. Lancet Oncol 2024;25(2):175-83. Abstract

Shore ND et al. Improved survival with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med 2026;394(6):563-75. Abstract

Stein MN et al. Pasritamig, a first-in-class, bispecific T-cell engager targeting human kallikrein 2, in metastatic castration-resistant prostate cancer: A phase I study. J Clin Oncol 2025;43(22):2515-26. Abstract

Tagawa ST et al. Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition). ESMO 2025;Abstract LBA6.

Yu EY et al. OMAHA-003: Phase 3 trial of CYP11A1 inhibitor opevesostat versus androgen receptor pathway inhibitor (ARPI) switch in participants (pts) with metastatic castration-resistant prostate cancer (mCRPC) after ARPI and taxane-based chemotherapy. Genitourinary Cancers Symposium 2026;Abstract TPS298.

Recent Advances in Cancer Care — New Paradigms, Novel Agents and What It Means for the Oncology Nurse: Management of Prostate Cancer

A Complimentary NCPD Symposium Held During the 51st Annual ONS Congress

Program Schedule — Central Time

11:45 AM – 12:15 PM — Registration and Lunch
12:15 PM – 1:45 PM — Educational Meeting

Location

San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, Texas
Hotel Phone: (210) 223-1000

Meeting Room

Grand Ballroom A-F (Third Floor)

No registration fee is charged for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.

Faculty

Michael Lai

Faculty

Michael Lai

MSN, ARNP, FNP-C

University of Washington School of Medicine Seattle, Washington

Advanced Practice Provider Fred Hutchinson Cancer Center Teaching Associate

Stacy E Walker

Faculty

Stacy E Walker

FNP-BC

Harvard Medical School Boston, Massachusetts

Nurse Practitioner Dana-Farber Cancer Institute

Evan Y Yu

Faculty

Evan Y Yu

MD

Fred Hutchinson Cancer Center, Seattle, Washington

Section Head, Medical Oncology, Clinical Research Division

Fred Hutchinson Cancer Research Consortium, Seattle, Washington

Medical Director, Clinical Research Support

University of Washington School of Medicine, Seattle, Washington

Professor of Medicine, Division of Hematology and Oncology, Department of Medicine

Scott T Tagawa

Moderator

Scott T Tagawa

MD, MS

Weill Cornell Medicine, New York, New York

Professor of Medicine and Urology

Meyer Cancer Center, New York, New York

Leader, GU Disease Management Team

Meeting space has been assigned to provide a symposium supported by Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Merck, and Novartis during the Oncology Nursing Society’s (ONS) 51st Annual Congress, May 13-17, 2026 in San Antonio, TX. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.

    Program Schedule — Central Time

    11:45 AM – 12:15 PM — Registration and Lunch
    12:15 PM – 1:45 PM — Educational Meeting

    MODULE 1: Hormonal Therapy for Nonmetastatic Hormone-Sensitive Prostate Cancer (nmHSPC)

    • Rationale for the evaluation of treatment intensification with androgen receptor (AR) pathway inhibitors for patients with nmHSPC
    • Key findings, including overall survival outcomes, with enzalutamide combined with leuprolide versus enzalutamide or leuprolide alone for men with nmHSPC and high-risk biochemical recurrence after definitive therapy
    • FDA approval and optimal application of enzalutamide with and without androgen deprivation therapy (ADT) for nmHSPC
    • Published data with ADT intensification with apalutamide with or without abiraterone for patients with high-risk biochemically recurrent nmHSPC

    MODULE 2: Hormonal Therapy for Metastatic HSPC (mHSPC)

    • Extended follow-up with abiraterone, enzalutamide and apalutamide in combination with ADT for men with mHSPC
    • Published data with the addition of darolutamide to ADT for patients with mHSPC; recent FDA approval of this regimen
    • Clinical factors guiding the selection of a specific secondary hormonal agent for patients with mHSPC; available datasets exploring the relative benefit of the various approved therapies in this setting
    • Published efficacy and safety data with darolutamide in combination with docetaxel and ADT for mHSPC; selection of optimal candidates for triplet therapy

    MODULE 3: Tolerability of Hormonal Therapy for Prostate Cancer

    • Incidence of hypertension and other cardiovascular (CV) adverse events (AEs) with different hormonal agents; optimal pretreatment assessment, on-therapy monitoring and management of CV events
    • Spectrum and frequency of central nervous system-related AEs (eg, seizures, cognitive decline, falls, fatigue) observed with hormonal therapy for patients with prostate cancer
    • Prevalence, mitigation and management of other notable side effects (eg, fractures, hot flashes, sarcopenias) with available hormonal therapies for prostate cancer
    • Tolerability profile of enzalutamide with and without ADT for nmHSPC; differences, if any, in the experience with this agent in later settings

    MODULE 4: Potential Role of Capivasertib in the Management of mHSPC

    • Frequency of PTEN deficiency in patients with prostate cancer; optimal approach to assessment of PTEN status
    • Biological justification for targeting the PI3K/AKT/mTOR pathway in prostate cancer, particularly in PTEN-deficient disease; mechanism of action of capivasertib
    • Recently presented efficacy and safety results with the addition of capivasertib to abiraterone/ADT for patients with de novo mHSPC and PTEN deficiency
    • Potential integration of capivasertib/abiraterone/ADT into treatment algorithms

    MODULE 5: Tolerability Profile of Capivasertib

    • Recommended side-effect management strategies for patients experiencing diarrhea and other gastrointestinal (GI) disorders while receiving capivasertib
    • Incidence of hyperglycemia among patients receiving capivasertib; appropriate glucose monitoring and interventions for those with elevated blood glucose levels
    • Optimal mitigation and management of cutaneous adverse reactions associated with capivasertib
    • Appropriate monitoring of complete blood counts for patients receiving capivasertib; recommended dose modifications for those experiencing cytopenias

    MODULE 6: Current and Future Role of PARP Inhibitors in Therapy for Metastatic Prostate Cancer

    • Incidence and clinical implications of BRCA1/2 and other homologous recombination repair (HRR) abnormalities in prostate cancer; recommended timing and optimal method for genetic testing
    • Biological basis for combining PARP inhibitors with secondary hormonal therapies in metastatic prostate cancer
    • Long-term efficacy and safety findings with olaparib/abiraterone, niraparib/abiraterone and talazoparib/enzalutamide as first-line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC)
    • FDA-approved indications for olaparib/abiraterone, niraparib/abiraterone and talazoparib/enzalutamide in mCRPC; optimal selection of patients for these approaches
    • Recently presented data with the addition of niraparib to abiraterone/prednisone for patients with mHSPC harboring alterations in HRR genes; clinical implications and integration into treatment algorithms
    • Other ongoing Phase III efforts evaluating combined PARP/AR pathway inhibition in this setting

    MODULE 7: Tolerability of PARP Inhibitors Used for Prostate Cancer

    • Incidence, timing and severity of common class-effect and agent-specific toxicities associated with PARP inhibitors for patients with metastatic prostate cancer
    • Optimal monitoring and management strategies for PARP inhibitor-related toxicities
    • Impact on the tolerability of PARP inhibitors when administered in combination with secondary hormonal therapy
    • Strategies for identifying the root cause of toxicities in patients receiving PARP inhibitor/secondary hormonal therapy combinations that may be attributable to either agent

    MODULE 8: Current and Future Role of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Prostate Cancer

    • Clinical relevance of PSMA expression in prostate cancer; mechanism of action of lutetium Lu 177 vipivotide tetraxetan
    • Published datasets with lutetium Lu 177 vipivotide tetraxetan for patients with taxane-naïve and taxane-pretreated PSMA-positive mCRPC
    • Appropriate sequencing of lutetium Lu 177 vipivotide tetraxetan with regard to other available therapies for mCRPC
    • Recently presented data with the addition of lutetium Lu 177 vipivotide tetraxetan to hormonal therapy for patients with PSMA-positive mHSPC; implications for clinical practice

    MODULE 9: Current and Future Role of Lutetium Lu 177 Vipivotide Tetraxetan in Treatment for Metastatic Prostate Cancer

    • Incidence, severity and management of commonly occurring AEs with radium-223 (eg, cytopenias, GI toxicity, peripheral edema, fractures)
    • Recommended algorithms for the management of common AEs observed in patients receiving lutetium Lu 177 vipivotide tetraxetan (eg, fatigue, dry mouth, GI toxicity, cytopenias)
    • Educating patients receiving radiopharmaceuticals regarding radiation risks and appropriate protection precautions
    • Other practical considerations related to the administration of novel radiopharmaceuticals for prostate cancer (eg, locating and referring patients to a nuclear medicine treatment center)

    Target Audience
    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of prostate cancer.

    Learning Objectives
    Upon completion of this activity, participants should be able to

    • Appraise published research findings on optimal management approaches for patients with biochemical recurrence following local treatment for prostate cancer, and counsel appropriate individuals regarding the potential benefits of FDA-approved systemic treatment options.
    • Evaluate the published research supporting the FDA approvals of secondary hormonal agents for nonmetastatic prostate cancer, and apply this information to educate patients about personalized treatment recommendations.
    • Explore available data with treatment intensification with cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer (mHSPC), and identify patients for these strategies.
    • Assess the available research supporting PARP inhibitors in combination with androgen receptor pathway inhibitors for patients with metastatic prostate cancer harboring a homologous recombination repair gene alteration, and discern how to optimally incorporate these agents into current clinical management algorithms.
    • Appreciate the biological rationale for targeting the PI3K/AKT/mTOR pathway for prostate cancer, and evaluate available data with novel AKT inhibitors in combination with hormonal therapy for patients with mHSPC and PTEN deficiency.
    • Review available Phase III data documenting the efficacy of various forms of radioligand therapy for metastatic prostate cancer, and consider the current and future clinical role of these strategies.
    • Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

    Accreditation Statement
    Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    Credit Designation Statements
    This educational activity for 1.5 contact hours is provided by Research To Practice.

    This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

    Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
    The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/ProstateCancer/ILNA.

    ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

    Credit Form
    To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

    Privacy Policy
    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    Unlabeled/Unapproved Uses Notice
    There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

    Content Validation and Disclosures
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — Mr Lai and Ms Walker have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

    Dr Yu — Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Johnson & Johnson, Lantheus, Merck, Novartis, Samsung Bioepis, Tolmar; Contracted Research: Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Dendreon Pharmaceuticals Inc, Lantheus, Merck, Pfizer Inc, Tyra Biosciences Inc. 

    MODERATOR
    Dr Tagawa — Consulting Agreements: AbbVie Inc, Abdera Therapeutics, Bayer HealthCare Pharmaceuticals, Biohaven, Blue Earth Diagnostics, Boston Scientific Corporation, Clarity Pharmaceuticals, Convergent Therapeutics Inc, Daiichi Sankyo Inc, EMD Serono Inc, GE Healthcare, Gilead Sciences Inc, Johnson & Johnson, Lantheus, Lilly, Merck, Myovant Sciences, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Telix Pharmaceuticals Limited; Contracted Research: AIQ Solutions, Bayer HealthCare Pharmaceuticals, Clarity Pharmaceuticals, Gilead Sciences Inc, Janux Therapeutics, Johnson & Johnson, Lilly, Merck, Novartis, Pfizer Inc, Telix Pharmaceuticals Limited; Data and Safety Monitoring Boards/Committees: Boston Scientific Corporation; Stock OPTIONS — Private Companies: Convergent Therapeutics.

    RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
    Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

    Supporters
    This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Merck, and Novartis.

    Location
    San Antonio Marriott Rivercenter
    101 Bowie St
    San Antonio, TX 78205
    Hotel Phone: (210) 223-1000

    Meeting Room
    Grand Ballroom A-F (Third Floor)

    Directions
    The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

     

    Registration is now closed.